is our passion

Banner Alzheimer's Institute, Phoenix, AZ, USA

Home / Banner Alzheimer’s Institute

Banner Alzheimer’s Institute

Banner Alzheimer’s Institute embraces a three-part mission to:

Set a new national standard of patient and family care
Conduct revolutionary studies in the detection and treatment of Alzheimer’s
Forge scientific collaborations that bring together institutions and disciplines internationally

Setting a new national standard of care

Banner Alzheimer’s Institute has introduced a new standard of care that provides ongoing hope and help for people with Alzheimer’s/dementia and their families. The Banner Alzheimer’s Institute standard of care combines exceptional services, groundbreaking research and innovative programs, including:

Complete medical, neurological and neuropsychological evaluations
Treatment and therapy
Support services that address both medical and non-medical needs
Comprehensive information and resources
Access to promising investigational treatments

Conducting revolutionary studies in the detection and treatment of Alzheimer’s

Our researchers envision, direct and analyze studies that scientists throughout the world regard as pivotal. Our team’s drive to end Alzheimer’s means we may pursue more than two dozen clinical trials at any given time. Our scientists are involved in:

Searching for and then tracking the neurological changes associated with the development of Alzheimer’s
Assessing the value, safety and tolerability of medications targeting Alzheimer’s physical and behavioral symptoms
Evaluating potential therapies that would prevent the onset of Alzheimer’s symptoms

Forging scientific collaborations that bring together institutions and disciplines internationally

Banner Alzheimer’s Institute is proud to partner with scientific, medical, academic and industry partners to end Alzheimer’s disease. Our collaborations include:

Arizona Alzheimer’s Consortium – Banner Alzheimer’s Institute launched and now leads the Arizona Alzheimer’s Consortium, the nation’s foremost model of statewide collaboration in Alzheimer’s disease research.

Alzheimer’s Prevention Initiative – Banner Alzheimer’s Institute championed and now oversees the Alzheimer’s Prevention Initiative (API), an international collaborative. Its goal is to launch a new era of Alzheimer’s prevention research by evaluating the most promising prevention treatments and to do so as quickly as possible. API includes scientists and physicians as well as industry and regulatory agency representatives from throughout the world.

Arizona State University-Banner Neurodegenerative Research Collaborative – Arizona State University (ASU) and Banner Health have formed a new research alliance to advance the scientific study, treatment and prevention of Alzheimer’s, Parkinson’s and other neurodegenerative diseases. This research partnership will include the launch of a new Arizona State University-Banner Neurodegenerative Disease Research Center on ASU’s Tempe campus.

Executive director of the Banner Alzheimer's Institute, CEO of Banner Research, and senior scientist at the Translational Genomics Research Institute
Banner Alzheimer’s Institute
August 31, 2023
A new study led by Mass General Brigham and a research team that included NOMIS researcher Eric Reiman and other investigators from across the United States and Colombia has shown that […]
May 15, 2023
In a great collaborative effort, NOMIS researcher Eric Reiman and study leaders Francisco Lopera, Joseph Arboleda-Velasquez, Diego Sepulveda-Falla and Yakeel Quiroz, together with their colleagues, have discovered a pathway for […]
December 21, 2020
In an article published on Dec. 7, 2020, Newsweek explores Alzheimer’s disease, highlighting the research of NOMIS scientist Eric Reiman and Salk Institute of Biological Studies president Rusty Gage. BY […]
July 28, 2020
NOMIS scientist Eric Reiman and colleagues have made a breakthrough in Alzheimer’s disease research, identifying a blood test that could help diagnose the disease. A new blood test demonstrated remarkable […]
November 4, 2019
In an article published in Nature Medicine, NOMIS scientist Eric Reiman, along with Joseph Arboleda-Velasquez, Yakeel Quiroz, Francisco Lopera and their colleagues, suggest that a mutation in APOE — the […]
November 21, 2017
“We are living in an age in which no single person, laboratory or discipline has the resources and skills to do everything that’s needed on one’s own.” Eric Reiman, executive […]
May 9, 2016
When NOMIS researcher Dr. Eric Reimann was invited to join the Arizona Alzheimer Consortium in Phoenix, he was a practicing psychiatrist who did not know much about the disease. Today, […]
December 1, 2022
Abstract: Introduction: Multiple positron emission tomography (PET) tracers are available for amyloid imaging, posing a significant challenge to consensus interpretation and quantitative analysis. We accordingly developed and validated a deep learning […]
December 1, 2022
Abstract: Background: The Colombian population, as well as those in other Latin American regions, arose from a recent tri-continental admixture among Native Americans, Spanish invaders, and enslaved Africans, all of whom […]
December 1, 2022
Abstract: Background: To promote the development of effective therapies, there is an important need to characterize the full spectrum of neuropathological changes associated with Alzheimer’s disease. In line with this need, […]
December 1, 2021
Abstract: Background: Neuroimaging studies of autosomal dominant Alzheimer’s disease (ADAD) enable characterization of the trajectories of cerebral amyloid-β (Aβ) and tau accumulation in the decades prior to clinical symptom onset. Longitudinal […]
May 1, 2021
Abstract: Background: Neurofilament light (NfL) is a promising biomarker of early neurodegeneration in Alzheimer’s disease (AD). We examined whether plasma NfL was associated with in vivo amyloid beta and tau, and […]
January 1, 2021
Abstract: Introduction: Cortical thinning is a marker of neurodegeneration in Alzheimer’s disease (AD). We investigated the age-related trajectory of cortical thickness across the lifespan (9-59 years) in a Colombian kindred with […]
February 4, 2019
Abstract: Background: Autosomal dominant Alzheimer’s disease (ADAD) is distinguished from late-onset AD by early striatal amyloid-β deposition. To determine whether striatal Pittsburgh compound B (PiB)-PET measurements of amyloid-β can help predict […]
June 1, 2018
Abstract: Background: Loss-of-function mutations in GRN cause frontotemporal lobar degeneration (FTLD). Patients with GRN mutations present with a uniform subtype of TAR DNA-binding protein 43 (TDP-43) pathology at autopsy (FTLD-TDP type […]